FMR LLC Files Schedule 13G Regarding Xenon Pharmaceuticals
FMR LLC has filed a Schedule 13G form indicating a change in its ownership stake in Xenon Pharmaceuticals.
Stocks · News reference
Xenon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026
Xenon Pharmaceuticals Inc. announced it will release its financial results for the third quarter of 2026 and provide a business update after the market close on November 9, 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Xenon Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Xenon Pharmaceuticals Inc. announced that it will present at four investor conferences during the fourth quarter of 2026.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals announced equity inducement grants for nine new non-officer employees, consisting of 24,250 share options and 14,250 restricted share units.
Xenon Pharmaceuticals Announces Positive Phase 1 Results and Preclinical Data for Acute Pain Candidates XEN1701 and XEN1120
Xenon Pharmaceuticals reported positive Phase 1 study results and new preclinical data for its acute pain candidates, XEN1701 and XEN1120, supporting their advancement into Phase 2 proof-of-concept studies.
Full Transcript: Xenon Pharmaceuticals Q2 2026 Earnings Call
Xenon Pharmaceuticals (NASDAQ:XENE) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by
Alpha Buying: 4 Biotech Stocks Insiders Are Betting On
I can sit through a biotech presentation and come away convinced that the company has discovered the answer to half the problems in modern medicine. The slides look terrific. The market opportunity is enormous.